The LEADS® Platform

The next step in data-driven drug discovery

Redefining diseases through multi-omic characterization

Advances in omics technologies allow comprehensive, cost-effective measurement of biomolecules across entire cellular systems. In drug discovery, this means that phenotypes are no longer defined by a few markers, but by quantitative changes in hundreds of thousands of cellular features.

Sinopia leverages these rich, system-level readouts to identify therapeutics that restore both local and global cellular states. The LEADS® (LEarn And DiScover) platform enables unbiased discovery while providing mechanistic insight into disease biology and therapeutic response.

What makes LEADS® different?

Unique metabolomics platform,
at scale

Combining pioneering advances in metabolomics technologies and data analysis is enabling our ability to study biology at an unprecedented level of biomolecular detail, using signals that most directly reflect cellular function. Metabolomics captures the integrated output of genetic, epigenetic, and environmental influences, providing a high-resolution view of cellular state. At the core of LEADS®, Sinopia has generated the largest metabolomics dataset for a small-molecule library to date, enabling system-level insights that reveal disease-relevant biology and therapeutic response with greater sensitivity, specificity, and predictivity to functional phenotype than approaches focused solely on upstream biomolecules.

Foundation models engineered for target discovery

Our proprietary deep learning models were built from the ground up to address the fundamental challenges of analyzing high-dimensional omics data. LEADS® applies artificial intelligence and machine learning, through foundation models, to transform raw multi-omics data into cross-context latent representations that increase the utility, comparability, and interpretability of generated data. By integrating these models with mechanistic systems biology, LEADS® decodes biological complexity to reveal novel targets and disease biology, and has been rigorously benchmarked to outperform state-of-the-art methods.

A platform validated by real success

LEADS® has already been validated in real-world drug discovery. The platform identified novel targets for Parkinson’s disease and oral mucositis, which have been successfully validated in vivo.